Equity Profile

SMMT

Summit Therapeutics Inc.

Health CareBiotechnology$11.2B

Aug10Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Summit Therapeutics Inc. is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will help gauge the company's ability to generate sales and expand its market presence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SMMT Q2-2026 Earnings Preview

Context

Company Snapshot

Summit Therapeutics Inc. is a biotechnology company focused on developing innovative medicines for serious diseases. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs, particularly in the areas of antibiotic resistance and rare diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

In Q1-2026, Summit Therapeutics reported an EPS of -$0.15, outperforming expectations by nearly 55%. The stock reacted positively, gaining over 3% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating a significant reaction to the upcoming earnings report, given the high implied volatility in the options market.

Bull Case

If Summit Therapeutics continues its trend of beating EPS estimates, it could indicate strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in the stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing financial health.

What are the revenue projections for the upcoming quarters?

Revenue growth is crucial for sustaining investor confidence and supporting the stock price, making this a key focus area.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Summit to outperform given its recent history of EPS surprises.

Supporting Evidence

Summit has beaten EPS estimates in 88% of the last eight quarters, indicating strong operational performance.

The options market is pricing a large move, suggesting that traders expect a significant reaction, which may not align with consensus expectations.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report will be critical in determining the company's trajectory, especially given its recent performance and market expectations.

Bull Confirmed If

An EPS of -$0.10 or better would confirm the bull case, indicating continued improvement in profitability.

Bear Confirmed If

An EPS worse than -$0.20 would confirm the bear case, suggesting potential operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±50.31%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a substantial potential price movement, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±50.3% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

109.2%

Calls (422K)P/C Ratio: 0.88Puts (205K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations, history suggests the stock could rise by around 5.8%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of about 1.4%, which could raise concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials and their expected timelines.
2Details on partnerships or collaborations that could enhance revenue.
3Management's commentary on market conditions and competitive landscape.
4Guidance on future revenue growth and profitability targets.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Tempus AI, Inc.

Company Snapshot

Summit Therapeutics Inc. is a biotechnology company focused on developing innovative medicines for serious diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth will help gauge the company's ability to generate sales and expand its market presence.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

SMMT Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+19.76%

Avg Stock Reaction

-4.23%

Last Quarter Recap

In Q1-2026, Summit Therapeutics reported an EPS of -$0.15, outperforming expectations by nearly 55%. The stock reacted positively, gaining over 3% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are anticipating a significant reaction to the upcoming earnings report, given the high implied volatility in the options market.

Bull Case

If Summit Therapeutics continues its trend of beating EPS estimates, it could indicate strong operational performance and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could lead to a sharp decline in the stock price, especially given the high implied volatility.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026?

Given the company's history of beating EPS estimates, the market will closely watch this figure to gauge ongoing financial health.

What are the revenue projections for the upcoming quarters?

Revenue growth is crucial for sustaining investor confidence and supporting the stock price, making this a key focus area.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Summit to outperform given its recent history of EPS surprises.

Supporting Evidence

Summit has beaten EPS estimates in 88% of the last eight quarters, indicating strong operational performance.

The options market is pricing a large move, suggesting that traders expect a significant reaction, which may not align with consensus expectations.

Key Risk

If the EPS comes in better than expected, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The upcoming earnings report will be critical in determining the company's trajectory, especially given its recent performance and market expectations.

Bull Confirmed If

An EPS of -$0.10 or better would confirm the bull case, indicating continued improvement in profitability.

Bear Confirmed If

An EPS worse than -$0.20 would confirm the bear case, suggesting potential operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±50.31%

Historical Avg

±5.8%

Pricing rich

The options market is pricing in a substantial potential price movement, indicating that traders expect significant volatility around the earnings report.

Options are pricing ±50.3% while SMMT has averaged ±5.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

1.0%

30d HV

109.2%

Calls (422K)P/C Ratio: 0.88Puts (205K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Summit beats expectations, history suggests the stock could rise by around 5.8%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further guidance.

Miss

If the company misses expectations, history suggests a potential decline of about 1.4%, which could raise concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on ongoing clinical trials and their expected timelines.
2Details on partnerships or collaborations that could enhance revenue.
3Management's commentary on market conditions and competitive landscape.
4Guidance on future revenue growth and profitability targets.